NKILT Therapeutics, Inc.

NKILT Therapeutics, Inc. is a preclinical cell therapy biotech startup focused on developing an innovative off-the-shelf approach to cancer treatment. Their proprietary and first-in-class engineered CIR™NK cells target HLA-G, a protein expressed in over 50% of hematologic and solid tumors. The company's technology aims to enhance the potency and persistence of natural killer (NK) cells, facilitating deeper and longer-lasting responses to cancer while improving scalability and patient access. Through their Chimeric ILT-Receptor (CIR™) technology, NKILT Therapeutics seeks to directly target and kill cancer cells, activate innate immunity, and address the tumor’s defense mechanisms. Their initial focus is on Acute Myeloid Leukemia (AML) as a pre-clinical/clinical proof of concept, with plans to expand to a range of HLA-G+ tumors, particularly solid tumors such as Colorectal Cancer (CRC), Bladder Cancer, Ovarian Cancer, Renal Cell Carcinoma (RCC), and Endometrial Cancer. Founded in 2021, NKILT Therapeutics operates in the Biotechnology, Health Care, and Health and Wellness industries. As of now, there is no publicly available information on their headquarters, last investment, or investors.